Article
Dormant DINs Revisited: MFN Pricing And The Evolving Impacts On Canada’s Patent Linkage Regime
Developments since then, including renewed U.S. attention to most‑favored‑nation (“MFN”) drug pricing have heightened the legal and policy concerns associated with that notice. In our view, those concerns merit renewed scrutiny.
Fasken